Category: Fellows Posters
Lung cancer is the most common malignancy worldwide. Despite significant advances in diagnosis and treatment, mortality rates remain high. Several PD1/PD-L1 immune checkpoint inhibitors have been introduced for the treatment of non-small cell lung cancer (NSCLC). However, there is a gap in knowledge regarding the prognostic utility of serine/threonine kinase 11 (STK11) as a potential predictor of response to immunotherapy. Biomarkers predicting response to immunotherapy could allow for early identification of non-responders. This study aims to determine if the presence of STK11 mutations could be used to predict resistance to immune checkpoint inhibitors (ICIs) in NSCLC patients.
This study is a retrospective chart review of patients who received immune checkpoint inhibitors at Memorial Healthcare System. This study will be submitted to the Institutional Review Board for approval. Data will be collected from the system’s electronic medical records and 150 patient records are expected to be reviewed. Patients will be included who are 18 years and older, diagnosed with stage IIIB or IV NSCLC, with or without driver mutations, and treated with immune checkpoint inhibitors. The electronic medical record will be reviewed to yield: gender, age, smoking status, race and ethnicity, stage, PDL-1 expression, STK11 mutational status, complete blood cell count with differentials, treatment regimen/immunotherapy agent used, and response to therapy. Data collected will be stratified by STK11 mutational status and reported in tabular format. The primary objective of this study is to assess patients with reported STK11 status that are receiving ICIs for NSCLC and compare response rates, progression-free survival (PFS), and overall survival (OS) between the STK11-mutated and non-mutated NSCLC groups. Additionally, the study will attempt to determine if differences exist in STK11 mutational status between race/ethnic groups and if there is a relationship between STK11 mutation and PD-L1 expression.